Living Cell Technologies - Latest News [Page 1]

Clinical trial of NTCELL for Parkinson’s disease

Thursday, 24 March 2016, 1:07 pm | Living Cell Technologies

24 March 2016 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies has received approval from the Auckland Hospital Research Review Committee for the Phase IIb clinical trial of NTCELL® for Parkinson’s disease. More >>

LCT completes $2.8m private placement and announces SPP

Wednesday, 17 February 2016, 12:19 pm | Living Cell Technologies

17 February 2016 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited has completed the placement of 54,607,546 shares at $0.05063 to wholesale investors resident in New Zealand, raising $2,764,621. The issue price ... More >>

LCT receives ethics approval for Phase IIb Parkinson’s trial

Wednesday, 3 February 2016, 4:47 pm | Living Cell Technologies

3 February 2016 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies has received approval from the Northern A Health and Disability Ethics Committee for the Phase IIb clinical trial of NTCELL® for Parkinson’s disease. ... More >>

NTCELL® Continues to Reverse the Progression of Parkinson’s

Wednesday, 27 January 2016, 1:05 pm | Living Cell Technologies

27 January 2016 – Sydney, Australia & Auckland, New Zealand – Over a year after treatment all four patients who took part in Living Cell Technologies Limited’s Phase I/IIa clinical study of NTCELL® for Parkinson’s disease remain well, and ... More >>

NTCELL® Clinical Study in Parkinson’s Meets Endpoints

Monday, 15 June 2015, 12:09 pm | Living Cell Technologies

NTCELL® Clinical Study in Parkinson’s Meets Endpoints Living Cell Technologies Advancing Regenerative Cell Therapy into Larger Phase IIb Study to Evaluate Its Potential as a Disease-modifying Treatment More >>

LCT completes patient implants in Parkinson’s trial

Monday, 15 December 2014, 12:38 pm | Living Cell Technologies

Living Cell Technologies Limited today announced that the final patient has been successfully implanted in its Phase I/IIa clinical trial of regenerative cell therapy NTCELL® for Parkinson’s disease. The operation took place at Auckland City Hospital ... More >>

LCT share purchase plan raises $1.08m

Thursday, 4 December 2014, 3:29 pm | Living Cell Technologies

Living Cell Technologies Limited today announced completion of its share purchase plan by the issue of 17,564,993 fully paid ordinary shares, raising an additional $1.08m. The shares will be allotted on 8 December 2014. More >>

LCT completes recruitment of patients in Parkinson’s trial

Monday, 3 November 2014, 12:19 pm | Living Cell Technologies

Living Cell Technologies Limited has completed recruitment of all patients for the Phase I/IIa clinical trial of the regenerative cell therapy NTCELL® for Parkinson’s disease. More >>

LCT JV secures funds to realise the potential of DIABECELL

Monday, 13 October 2014, 10:01 am | Living Cell Technologies

13 October 2014 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited (LCT) announced that its 50% owned joint venture Diatranz Otsuka Limited (DOL) has agreed to a loan facility of up to NZD42m from its other shareholder ... More >>

LCT announces completion of $3m placement and SPP

Wednesday, 8 October 2014, 12:34 pm | Living Cell Technologies

8 October 2014 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited today announced the placement of 49,410,392 fully paid Ordinary shares at $0.0608 to eligible persons resident in New Zealand, raising $3m. The issue ... More >>

LCT collaborates to develop novel neurological treatments

Monday, 29 September 2014, 5:15 pm | Living Cell Technologies

Living Cell Technologies Limited has formed a collaboration with the Centre for Brain Research (CBR). The research collaboration will identify additional neurodegenerative disease targets for clinical studies of LCT’s lead product NTCELL®. More >>

LCT Appoints Scientific Advisors

Tuesday, 23 September 2014, 1:23 pm | Living Cell Technologies

Living Cell Technologies Limited (LCT) has appointed three high-level scientific advisors to review and support its work as NTCELL progresses towards commercialisation. The appointments are Professors Anne Young from Harvard, Roger Barker from Cambridge ... More >>

Successful second implant of NTCELL for Parkinson’s

Monday, 18 August 2014, 3:34 pm | Living Cell Technologies

18 August 2014 – Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited today announced that a second patient has been successfully implanted at Auckland City Hospital in the clinical trial of the regenerative cell therapy NTCELL® ... More >>

Dr Ken Taylor appointed Chief Executive

Tuesday, 8 July 2014, 1:19 pm | Living Cell Technologies

Living Cell Technologies Limited today announced that Dr Ken Taylor has been appointed Chief Executive. Ken was appointed NTCELL Program Director in February and became Acting Chief Executive in April. He has been successful resuming patient recruitment ... More >>

LCT Parkinson’s trial resumes patient recruitment

Monday, 23 June 2014, 1:00 pm | Living Cell Technologies

Living Cell Technologies Limited today announced that it has received the necessary regulatory approval to resume recruitment of the remaining three patients in the Phase I/IIa clinical trial of NTCELL® in Parkinson’s disease. More >>

Withdrawal of NTCELL pre-clinical study

Thursday, 20 February 2014, 4:00 pm | Living Cell Technologies

Living Cell Technologies Limited today announced that it is withdrawing the publication of the pre-clinical study of the effects of NTCELL in a rat model of Parkinson’s disease. The data will also be withdrawn from all regulatory documentation. More >>

NTCELL clinical trial: Recruitment of further patients

Monday, 25 November 2013, 1:35 pm | Living Cell Technologies

Living Cell Technologies Limited today announced that the independent data safety monitoring board (DSMB) has reviewed the safety data from the initial patient in the Phase I/IIa clinical trial of NTCELL and advised that implants for the additional ... More >>

Living Cell Technologies a finalist

Thursday, 28 March 2013, 12:05 pm | Living Cell Technologies

Living Cell Technologies a finalist in 2013 New Zealand Hi-Tech Awards Auckland, 28 March 2013 – Living Cell Technologies was last night announced as a finalist in the 2013 New Zealand Hi-Tech Awards. The company is a finalist in the Cisco Hi-Tech ... More >>

Living Cell Technologies Awarded NZBIO Company of the Year

Wednesday, 20 March 2013, 11:09 am | Living Cell Technologies

Living Cell Technologies Limited Company Announcement Living Cell Technologies Awarded NZBIO Company of the Year More >>

LCT appoints Chief Science and Medical Officer

Monday, 10 December 2012, 11:46 am | Living Cell Technologies

10 December, 2012 Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced the appointment of Dr Paul Tan to the position of Chief Science and Medical Officer (CSMO). More >>

 

 

InfoPages Links

 
 
 

LATEST HEADLINES

 
 
 
InfoPages
Search Scoop  
 
 
Powered by Vodafone
NZ independent news